CELL DEL
LIVE

Serial Number

99926297

Owner

CellarisBio, LLC

Attorney

Jianmin Zhou

First Use Date

Jan 5, 2026

Filing Date

Jul 7, 2026

Add to watchlist:

No watchlists yet
View on USPTO

CELL DEL Trademark

Serial Number: 99926297

CELL DEL is a trademark filed by CellarisBio, LLC on July 7, 2026. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

CellarisBio, LLC

9276 Scranton Rd, Suite 500
San Diego, CA 92121

Entity Type: 16

Trademark Details

Filing Date

July 7, 2026

Registration Date

Not Registered

First Use Anywhere

January 5, 2026

First Use in Commerce

January 5, 2026

Goods & Services

Reagents for cellular DNA-encoded library screening and selection; reagents for cellular ligand discovery assays; reagents for cell-based compound screening and target engagement assays; reagents for DNA-encoded library-based drug discovery; reagents for enrichment, identification, validation, and characterization of ligand-target interactions in cells; biochemical reagents for cellular screening assays; assay reagents for identifying bioactive compounds in living cells; reagents for affinity selection and molecular interaction analysis; nucleic acid-tagged chemical libraries; chemical preparations for scientific purposes; biochemical reagents for scientific use; proteins, enzymes, nucleic acids, and chemical reagents for scientific research use; diagnostic preparations for scientific and laboratory research use; reagents for therapeutics discovery and drug discovery research.

Research and development services in cellular DNA-encoded library drug discovery; research and development in cell-based ligand discovery and target identification; pharmaceutical drug discovery and development services; research and development in therapeutics discovery; research and development in small-molecule discovery using DNA-encoded libraries; research and development in cellular target engagement and compound validation; conducting cellular screening, affinity selection, hit identification, hit validation, and lead discovery for scientific and pharmaceutical research; technology research in therapeutics discovery and drug discovery platforms; pharmaceutical product development relating to small molecules, molecular glues, degraders, peptides, antibodies, and therapeutic modalities; research and development of therapeutic compounds targeting intracellular proteins, membrane proteins, protein complexes, transcription factors, and signaling proteins.

Filing History

APPLICATION FILING RECEIPT MAILED
Jul 7, 2026 MAFR
NEW APPLICATION ENTERED
Jul 7, 2026 NWAP